FDA announces Evusheld is not currently authorized for emergency use in the U.S.

FDA ^ | 26 Jan 2023 | FDA PSA

[blueplum]

Update [1/26/2023] The U.S. Food and Drug Administration today revised the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, Evusheld is not currently authorized for use in the U.S. until further notice by the Agency.

Data show Evusheld is unlikely to be active against certain SARS-CoV-2 variants. According to the most recent CDC Nowcast data, these variants are projected to be responsible for more than 90% of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants....

... like other viruses, SARS-CoV-2 can mutate over time, resulting in certain products not working against certain variants. This is the case with Evusheld and prompted the changes to the authorization that FDA is making today....

...Because of its similarity to variants that are not neutralized by Evusheld (e.g., XBB), FDA does not anticipate that Evusheld will neutralize XBB.1.5. This means that Evusheld may not provide protection against developing COVID-19 for individuals who have received Evusheld and are later exposed to XBB.1.5....

[blueplum]

Two more monoclonals rendered ineffective by further mutations of the covid virus. Facilities are asked to preserve their supplies of Evushield in the event future mutations are found to once again become succeptible to Evushield. Evushield is a monoclonal cocktail used to treat mild to moderate covid regardless of vaccine status.

[Wally_Kalbacken]

Personally, I prefer Bomazcromib extended release. Or the old standby, Hectranofib, in those big-ass capsules.